Title |
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial
|
---|---|
Published in |
Trials, October 2020
|
DOI | 10.1186/s13063-020-04775-4 |
Pubmed ID | |
Authors |
Ricardo Palacios, Elizabeth González Patiño, Roberta de Oliveira Piorelli, Monica Tilli Reis Pessoa Conde, Ana Paula Batista, Gang Zeng, Qianqian Xin, Esper G. Kallas, Jorge Flores, Christian F. Ockenhouse, Christopher Gast |
X Demographics
The data shown below were collected from the profiles of 181 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 12 | 7% |
Brazil | 12 | 7% |
Chile | 10 | 6% |
Indonesia | 8 | 4% |
Philippines | 5 | 3% |
United Kingdom | 4 | 2% |
Mexico | 4 | 2% |
India | 3 | 2% |
France | 3 | 2% |
Other | 25 | 14% |
Unknown | 95 | 52% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 154 | 85% |
Scientists | 16 | 9% |
Practitioners (doctors, other healthcare professionals) | 9 | 5% |
Science communicators (journalists, bloggers, editors) | 2 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 952 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 952 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 195 | 20% |
Student > Master | 88 | 9% |
Researcher | 66 | 7% |
Student > Ph. D. Student | 59 | 6% |
Other | 42 | 4% |
Other | 140 | 15% |
Unknown | 362 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 232 | 24% |
Nursing and Health Professions | 90 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 51 | 5% |
Biochemistry, Genetics and Molecular Biology | 37 | 4% |
Immunology and Microbiology | 26 | 3% |
Other | 125 | 13% |
Unknown | 391 | 41% |